Skip to main content
Top

01-08-2014 | Breast cancer | Book chapter | Article

9. Breast MRI for Diagnosis and Staging of Breast Cancer

Authors: Riham H. El Khouli, MD, PhD, Michael A. Jacobs, PhD, Katarzyna J. Macura, MD, PhD

Publisher: Springer New York

Abstract

Breast magnetic resonance imaging (MRI) has been a very fast developing tool for the assessment of breast cancer and quickly moved from research to clinical settings. It is being used to evaluate patients with specific indications and as a screening tool for high-risk patients. The value of breast MRI arises from its very high sensitivity in detecting breast cancer but more importantly from its ability to functionally assess physiological and biochemical properties of breast tissue, thus helping in the management of breast cancer, including the assessment of the extent of disease, the detection of contralateral disease, and the evaluation of treatment response. Response to treatment has been traditionally assessed based on gross tumor size change, a parameter that has been shown to have limitations in the accurate prediction of the treatment response and outcome. MRI offers functional methods to aid treatment response assessment that better reflect the viability of tumor and tumor burden versus just size changes. Understanding the indications for breast MRI, diagnostic criteria utilized to detect and characterize breast cancer, and technical challenges are important in both clinical and research settings. In this chapter we discuss the utilization of breast MRI in breast cancer diagnosis and staging, including the review of patterns of enhancement and principles of pharmacokinetic modeling for dynamic contrast-enhanced MRI, application of diffusion-weighted imaging and MR-guided breast biopsy, as well as review of technical considerations for optimization of image acquisition and assessment of treatment response.
Literature
1.
Glunde K, Jacobs MA, Pathak AP, Artemov D, Bhujwalla ZM. Molecular and functional imaging of breast cancer. NMR Biomed. 2009;22(1):92–103.PubMedCrossRef
2.
Kerlikowske K, Cook AJ, Buist DS, Cummings SR, Vachon C, Vacek P, et al. Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use. J Clin Oncol. 2010;28(24):3830–7.PubMedCrossRefPubMedCentral
3.
McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1159–69.PubMedCrossRef
4.
Yaghjyan L, Colditz GA, Collins LC, Schnitt SJ, Rosner B, Vachon C, et al. Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics. J Natl Cancer Inst. 2011;103(15):1179–89.PubMedCrossRefPubMedCentral
5.
American College of Radiology. Breast imaging and reporting data system. 5th ed. Reston: American College of Radiology; 2004.
6.
Nunes LW, Schnall MD, Orel SG. Update of breast MR imaging architectural interpretation model. Radiology. 2001;219(2):484–94.PubMedCrossRef
7.
Schnall MD, Rosten S, Englander S, Orel SG, Nunes LW. A combined architectural and kinetic interpretation model for breast MR images. Acad Radiol. 2001;8(7):591–7.PubMedCrossRef
8.
Liberman L, Morris EA, Lee MJ, Kaplan JB, LaTrenta LR, Menell JH, et al. Breast lesions detected on MR imaging: features and positive predictive value. AJR Am J Roentgenol. 2002;179(1):171–8.PubMedCrossRef
9.
Nunes LW, Schnall MD, Siegelman ES, Langlotz CP, Orel SG, Sullivan D, et al. Diagnostic performance characteristics of architectural features revealed by high spatial-resolution MR imaging of the breast. AJR Am J Roentgenol. 1997;169(2):409–15.PubMedCrossRef
10.
Morakkabati-Spitz N, Leutner C, Schild H, Traeber F, Kuhl C. Diagnostic usefulness of segmental and linear enhancement in dynamic breast MRI. Eur Radiol. 2005;15(9):2010–7.PubMedCrossRef
11.
Bluemke DA, Gatsonis CA, Chen MH, DeAngelis GA, DeBruhl N, Harms S, et al. Magnetic resonance imaging of the breast prior to biopsy. JAMA. 2004;292(22):2735–42.PubMedCrossRef
12.
El Khouli RH, Macura KJ, Kamel IR, Jacobs MA, Bluemke DA. 3-T dynamic contrast-enhanced MRI of the breast: pharmacokinetic parameters versus conventional kinetic curve analysis. AJR Am J Roentgenol. 2011;197(6):1498–505.PubMedCrossRefPubMedCentral
13.
Kaiser WA, Zeitler E. MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. Radiology. 1989;170(3 Pt 1):681–6.PubMedCrossRef
14.
Kinkel K, Helbich TH, Esserman LJ, Barclay J, Schwerin EH, Sickles EA, et al. Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability. AJR Am J Roentgenol. 2000;175(1):35–43.PubMedCrossRef
15.
Kuhl CK, Mielcareck P, Klaschik S, Leutner C, Wardelmann E, Gieseke J, et al. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology. 1999;211(1):101–10.PubMedCrossRef
16.
Kaiser WA, Deimling M. [A new multislice measurement sequence for the complete dynamic MR examination of the larger organs: application to the breast]. Eine neue Multischicht-Messsequenz fur die komplette dynamische MR-Untersuchung an grosseren Organen: Anwendung an der Brust. Rofo. 1990;152(5):577–82.PubMedCrossRef
17.
Kuhl CK, Schild HH, Morakkabati N. Dynamic bilateral contrast-enhanced MR imaging of the breast: trade-off between spatial and temporal resolution. Radiology. 2005;236(3):789–800.PubMedCrossRef
18.
El Khouli RH, Macura KJ, Jacobs MA, Khalil TH, Kamel IR, Dwyer A, et al. Dynamic contrast-enhanced MRI of the breast: quantitative method for kinetic curve type assessment. AJR Am J Roentgenol. 2009;193(4):W295–300.PubMedCrossRefPubMedCentral
19.
Boetes C, Barentsz JO, Mus RD, van der Sluis RF, van Erning LJ, Hendriks JH, et al. MR characterization of suspicious breast lesions with a gadolinium-enhanced TurboFLASH subtraction technique. Radiology. 1994;193(3):777–81.PubMedCrossRef
20.
Mahfouz AE, Sherif H, Saad A, Taupitz M, Filimonow S, Kivelitz D, et al. Gadolinium-enhanced MR angiography of the breast: is breast cancer associated with ipsilateral higher vascularity? Eur Radiol. 2001;11(6):965–9.PubMedCrossRef
21.
Sardanelli F, Iozzelli A, Fausto A, Carriero A, Kirchin MA. Gadobenate dimeglumine-enhanced MR imaging breast vascular maps: association between invasive cancer and ipsilateral increased vascularity. Radiology. 2005;235(3):791–7.PubMedCrossRef
22.
Jackson A, O’Connor JP, Parker GJ, Jayson GC. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res. 2007;13(12):3449–59.PubMedCrossRef
23.
O’Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer. 2007;96(2):189–95.PubMedCrossRefPubMedCentral
24.
Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr. 1991;15(4):621–8.PubMedCrossRef
25.
Taylor JS, Tofts PS, Port R, Evelhoch JL, Knopp M, Reddick WE, et al. MR imaging of tumor microcirculation: promise for the new millennium. J Magn Reson Imaging. 1999;10(6):903–7.PubMedCrossRef
26.
Evelhoch JL. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging. 1999;10(3):254–9.PubMedCrossRef
27.
Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10(3):223–32.PubMedCrossRef
28.
Parker GJ, Roberts C, Macdonald A, Buonaccorsi GA, Cheung S, Buckley DL, et al. Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn Reson Med. 2006;56(5):993–1000.PubMedCrossRef
29.
Buonaccorsi GA, Roberts C, Cheung S, Watson Y, O’Connor JP, Davies K, et al. Comparison of the performance of tracer kinetic model-driven registration for dynamic contrast enhanced MRI using different models of contrast enhancement. Acad Radiol. 2006;13(9):1112–23.PubMedCrossRef
30.
Roberts C, Issa B, Stone A, Jackson A, Waterton JC, Parker GJ. Comparative study into the robustness of compartmental modeling and model-free analysis in DCE-MRI studies. J Magn Reson Imaging. 2006;23(4):554–63.PubMedCrossRef
31.
Huang W, Li X, Morris EA, Tudorica LA, Seshan VE, Rooney WD, et al. The magnetic resonance shutter speed discriminates vascular properties of malignant and benign breast tumors in vivo. Proc Natl Acad Sci U S A. 2008;105(46):17943–8.PubMedCrossRefPubMedCentral
32.
Haris M, Husain N, Singh A, Awasthi R, Singh Rathore RK, Husain M, et al. Dynamic contrast-enhanced (DCE) derived transfer coefficient (ktrans) is a surrogate marker of matrix metalloproteinase 9 (MMP-9) expression in brain tuberculomas. J Magn Reson Imaging. 2008;28(3):588–97.PubMedCrossRef
33.
Yankeelov TE, Luci JJ, Lepage M, Li R, Debusk L, Lin PC, et al. Quantitative pharmacokinetic analysis of DCE-MRI data without an arterial input function: a reference region model. Magn Reson Imaging. 2005;23(4):519–29.PubMedCrossRef
34.
Yankeelov TE, Rooney WD, Huang W, Dyke JP, Li X, Tudorica A, et al. Evidence for shutter-speed variation in CR bolus-tracking studies of human pathology. NMR Biomed. 2005;18(3):173–85.PubMedCrossRef
35.
Jackson A, Jayson GC, Li KL, Zhu XP, Checkley DR, Tessier JJ, et al. Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. Br J Radiol. 2003;76(903):153–62.PubMedCrossRef
36.
Bhujwalla ZM, Artemov D, Glockner J. Tumor angiogenesis, vascularization, and contrast-enhanced magnetic resonance imaging. Top Magn Reson Imaging. 1999;10(2):92–103.PubMedCrossRef
37.
Mussurakis S, Buckley DL, Horsman A. Dynamic MRI of invasive breast cancer: assessment of three region-of-interest analysis methods. J Comput Assist Tomogr. 1997;21(3):431–8.PubMedCrossRef
38.
Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology. 1986;161(2):401–7.PubMedCrossRef
39.
Englander SA, Ulug AM, Brem R, Glickson JD, van Zijl PC. Diffusion imaging of human breast. NMR Biomed. 1997;10(7):348–52.PubMedCrossRef
40.
Guo Y, Cai YQ, Cai ZL, Gao YG, An NY, Ma L, et al. Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. J Magn Reson Imaging. 2002;16(2):172–8.PubMedCrossRef
41.
Sinha S, Lucas-Quesada FA, Sinha U, DeBruhl N, Bassett LW. In vivo diffusion-weighted MRI of the breast: potential for lesion characterization. J Magn Reson Imaging. 2002;15(6):693–704.PubMedCrossRef
42.
Woodhams R, Matsunaga K, Iwabuchi K, Kan S, Hata H, Kuranami M, et al. Diffusion-weighted imaging of malignant breast tumors: the usefulness of apparent diffusion coefficient (ADC) value and ADC map for the detection of malignant breast tumors and evaluation of cancer extension. J Comput Assist Tomogr. 2005;29(5):644–9.PubMedCrossRef
43.
Woodhams R, Matsunaga K, Kan S, Hata H, Ozaki M, Iwabuchi K, et al. ADC mapping of benign and malignant breast tumors. Magn Reson Med Sci. 2005;4(1):35–42.PubMedCrossRef
44.
Park MJ, Cha ES, Kang BJ, Ihn YK, Baik JH. The role of diffusion-weighted imaging and the apparent diffusion coefficient (ADC) values for breast tumors. Korean J Radiol. 2007;8(5):390–6.PubMedCrossRefPubMedCentral
45.
Ei Khouli RH, Jacobs MA, Mezban SD, Huang P, Kamel IR, Macura KJ, et al. Diffusion-weighted imaging improves the diagnostic accuracy of conventional 3.0-T breast MR imaging. Radiology. 2010;256(1):64–73.PubMedCrossRefPubMedCentral
46.
Pereira FP, Martins G, Figueiredo E, Domingues MN, Domingues RC, da Fonseca LM, et al. Assessment of breast lesions with diffusion-weighted MRI: comparing the use of different b values. AJR Am J Roentgenol. 2009;193(4):1030–5.PubMedCrossRef
47.
Bogner W, Gruber S, Pinker K, Grabner G, Stadlbauer A, Weber M, et al. Diffusion-weighted MR for differentiation of breast lesions at 3.0 T: how does selection of diffusion protocols affect diagnosis? Radiology. 2009;253(2):341–51.PubMedCrossRef
48.
Marini C, Iacconi C, Giannelli M, Cilotti A, Moretti M, Bartolozzi C. Quantitative diffusion-weighted MR imaging in the differential diagnosis of breast lesion. Eur Radiol. 2007;17(10):2646–55.PubMedCrossRef
49.
Partridge SC, McKinnon GC, Henry RG, Hylton NM. Menstrual cycle variation of apparent diffusion coefficients measured in the normal breast using MRI. J Magn Reson Imaging. 2001;14(4):433–8.PubMedCrossRef
50.
James K, Eisenhauer E, Christian M, Terenziani M, Vena D, Muldal A, et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst. 1999;91(6):523–8.PubMedCrossRef
51.
Therasse P. Measuring the clinical response. What does it mean? Eur J Cancer. 2002;38(14):1817–23.PubMedCrossRef
52.
Tran LN, Brown MS, Goldin JG, Yan X, Pais RC, McNitt-Gray MF, et al. Comparison of treatment response classifications between unidimensional, bidimensional, and volumetric measurements of metastatic lung lesions on chest computed tomography. Acad Radiol. 2004;11(12):1355–60.PubMedCrossRef
53.
Park JO, Lee SI, Song SY, Kim K, Kim WS, Jung CW, et al. Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol. 2003;33(10):533–7.PubMedCrossRef
54.
Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, et al. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol. 2005;184(6):1774–81.PubMedCrossRef
55.
Jacobs MA, Stearns V, Wolff AC, Macura K, Argani P, Khouri N, et al. Multiparametric magnetic resonance imaging, spectroscopy and multinuclear ((2)(3)Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer. Acad Radiol. 2010;17(12):1477–85.PubMedCrossRefPubMedCentral
56.
Marinovich ML, Sardanelli F, Ciatto S, Mamounas E, Brennan M, Macaskill P, et al. Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI. Breast. 2012;21(5):669–77.PubMedCrossRef
57.
Wiener JI, Schilling KJ, Adami C, Obuchowski NA. Assessment of suspected breast cancer by MRI: a prospective clinical trial using a combined kinetic and morphologic analysis. AJR Am J Roentgenol. 2005;184(3):878–86.PubMedCrossRef
58.
Padhani AR, Hayes C, Assersohn L, Powles T, Makris A, Suckling J, et al. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology. 2006;239(2):361–74.PubMedCrossRef
59.
Jacobs MA, Ouwerkerk R, Wolff AC, Gabrielson E, Warzecha H, Jeter S, et al. Monitoring of neoadjuvant chemotherapy using multiparametric, (2)(3)Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer. Breast Cancer Res Treat. 2011;128(1):119–26.PubMedCrossRefPubMedCentral
60.
Wasser K, Klein SK, Fink C, Junkermann H, Sinn HP, Zuna I, et al. Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution. Eur Radiol. 2003;13(1):80–7.PubMed
61.
Pickles MD, Lowry M, Manton DJ, Gibbs P, Turnbull LW. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2005;91(1):1–10.PubMedCrossRef
62.
Malayeri AA, El Khouli RH, Zaheer A, Jacobs MA, Corona-Villalobos CP, Kamel IR, et al. Principles and applications of diffusion-weighted imaging in cancer detection, staging, and treatment follow-up. Radiographics. 2011;31(6):1773–91.PubMedCrossRef
63.
Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst. 2000;92(24):2029–36.PubMedCrossRef
64.
Chenevert TL, Meyer CR, Moffat BA, Rehemtulla A, Mukherji SK, Gebarski SS, et al. Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging. 2002;1(4):336–43.PubMedCrossRef
65.
Partridge SC, DeMartini WB, Kurland BF, Eby PR, White SW, Lehman CD. Quantitative diffusion-weighted imaging as an adjunct to conventional breast MRI for improved positive predictive value. AJR Am J Roentgenol. 2009;193(6):1716–22.PubMedCrossRef
66.
Sharma U, Danishad KK, Seenu V, Jagannathan NR. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed. 2009;22(1):104–13.PubMedCrossRef
67.
Park SH, Moon WK, Cho N, Song IC, Chang JM, Park IA, et al. Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology. 2010;257(1):56–63.PubMedCrossRef
68.
Woodhams R, Kakita S, Hata H, Iwabuchi K, Kuranami M, Gautam S, et al. Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging – comparison with contrast-enhanced MR imaging and pathologic findings. Radiology. 2010;254(2):357–66.PubMedCrossRef
69.
Wu LM, Hu JN, Gu HY, Hua J, Chen J, Xu JR. Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer? Breast Cancer Res Treat. 2012;135(1):17–28.PubMedCrossRef
70.
Kuhl CK, Jost P, Morakkabati N, Zivanovic O, Schild HH, Gieseke J. Contrast-enhanced MR imaging of the breast at 3.0 and 1.5 T in the same patients: initial experience. Radiology. 2006;239(3):666–76.PubMedCrossRef
71.
Rakow-Penner R, Daniel B, Yu H, Sawyer-Glover A, Glover GH. Relaxation times of breast tissue at 1.5 T and 3 T measured using IDEAL. J Magn Reson Imaging. 2006;23(1):87–91.PubMedCrossRef
72.
Rausch DR, Hendrick RE. How to optimize clinical breast MR imaging practices and techniques on Your 1.5-T system. Radiographics. 2006;26(5):1469–84.PubMedCrossRef
73.
Lehman CD, Blume JD, Thickman D, Bluemke DA, Pisano E, Kuhl C, et al. Added cancer yield of MRI in screening the contralateral breast of women recently diagnosed with breast cancer: results from the International Breast Magnetic Resonance Consortium (IBMC) trial. J Surg Oncol. 2005;92(1):9–15; discussion 15–6.PubMedCrossRef
74.
Harvey JA, Hendrick RE, Coll JM, Nicholson BT, Burkholder BT, Cohen MA. Breast MR imaging artifacts: how to recognize and fix them. Radiographics. 2007;27 Suppl 1:S131–45.PubMedCrossRef
75.
Nunes LW, Schnall MD, Orel SG, Hochman MG, Langlotz CP, Reynolds CA, et al. Breast MR imaging: interpretation model. Radiology. 1997;202(3):833–41.PubMedCrossRef
76.
Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging. 1997;7(1):91–101.PubMedCrossRef
77.
Tofts PS, Berkowitz B, Schnall MD. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn Reson Med. 1995;33(4):564–8.PubMedCrossRef
78.
Collins DJ, Padhani AR. Dynamic magnetic resonance imaging of tumor perfusion. Approaches and biomedical challenges. IEEE Eng Med Biol Mag. 2004;23(5):65–83.PubMedCrossRef
79.
Dale BM, Jesberger JA, Lewin JS, Hillenbrand CM, Duerk JL. Determining and optimizing the precision of quantitative measurements of perfusion from dynamic contrast enhanced MRI. J Magn Reson Imaging. 2003;18(5):575–84.PubMedCrossRef
80.
Kanal E, Barkovich AJ, Bell C, Borgstede JP, Bradley Jr WG, Froelich JW, et al. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol. 2007;188(6):1447–74.PubMedCrossRef
81.
Braun M, Polcher M, Schrading S, Zivanovic O, Kowalski T, Flucke U, et al. Influence of preoperative MRI on the surgical management of patients with operable breast cancer. Breast Cancer Res Treat. 2008;111(1):179–87.PubMedCrossRef
82.
Mameri CS, Kemp C, Goldman SM, Sobral LA, Ajzen S. Impact of breast MRI on surgical treatment, axillary approach, and systemic therapy for breast cancer. Breast J. 2008;14(3):236–44.PubMedCrossRef
83.
Meeuwis C, Veltman J, van Hall HN, Mus RD, Boetes C, Barentsz JO, et al. MR-guided breast biopsy at 3 T: diagnostic yield of large core needle biopsy compared with vacuum-assisted biopsy. Eur Radiol. 2012;22(2):341–9.PubMedCrossRefPubMedCentral
84.
El Khouli RH, Macura KJ, Barker PB, Elkady LM, Jacobs MA, Vogel-Claussen J, et al. MRI-guided vacuum-assisted breast biopsy: a phantom and patient evaluation of targeting accuracy. J Magn Reson Imaging. 2009;30(2):424–9.PubMedCrossRefPubMedCentral